StemCell Therapy

Some AAV manufacturing processes use adherent cells grown in stacked trays. AGTC sees that model as a barrier to scaling, pointing to the inability to scale processes up by adding volume. Scaling of adherent cell processes requires additional surface area.

AGTC overcame that limitation by designing a process that makes use of bioreactors, enabling it to scale up from 50 L to 500 L and beyond without significantly increasing its footprint. AGTC enhanced the approach with changes it says improved yield by more than 10 fold.

We adjusted the upstream process which uses two HSV helper viruses to increase AAV production in a number of ways, one of which was optimizing the ratio and amount of the two viruses. Further, we optimized the bioreactor conditions to increase cell density. Both of these changes led to substantial increases in volumetric productivity, said AGTC CEO Sue Washer.

Adjusting the ratios and conditions of the process enabled AGTC to make more vectors and increase the percentage of them that are full. AGTC is now achieving finished product specifications that demonstrate nearly 90% full capsids.

Washer went on to say that AGTC also optimized the column chromatography purification process to more completely separate residuals from vectors. In doing so, AGTC was able to collect a higher quality product from the elution peak, according to Washer.

Using the process, AGTC estimates it could generate 2,000 ophthalmology gene therapy doses from a 50-L manufacturing run. That would enable AGTC to support its move into late-phase clinical trials using a relatively small manufacturing footprint.

The improvements could prove particularly valuable to AGTC as it expands beyond diseases affecting the eye. The gene therapy doses needed to treat ocular diseases are far smaller than those required to address conditions affecting other organs, which typically need to be given systemically.

The industry-wide move from rare diseases treated via local delivery to more common conditions that require systemic administration is putting a strain on manufacturing capacity. If AGTC is right, its process will equip it to manage the manufacturing side of the shift in therapeutic focus better than some other gene therapy companies.

AGTC is now advancing programs that will enable it to start putting that hypothesis to the test. While AGTCs clinical pipeline is focused on rare genetic eye diseases, the biotech is working to get gene therapies for central nervous system disorders into human testing. Washer is alert to the implications of AGTCs manufacturing process.

Improved yields makes use of gene therapy for larger patient populations or systemic diseases much more achievable, said Washer.

AGTC is working to further improve the system. Ongoing areas of activity relate to purification, where Washer sees opportunities to eliminate all process residuals, and the improvement of yields and the percentage of full capsids.

The nature of the process means manufacturing runs could become more productive even in the absence of further technological advances. Simply running the same process at a larger scale should confer some benefits.

Continuing to scale to larger bioreactors could continue to increase the number of doses from a single run and drive down costs as bioreactor scale-up does not put a burden on factory space or FTE needed like the use of plastic flat-stock does, said Washer.

Read the rest here:
Using HSV helper viruses to increase AAV production - BioPharma-Reporter.com

NEW YORK, Sept. 23, 2020 /PRNewswire/ --Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced today the signing of a Sponsored Research Agreement (SRA) with Duke University to use the MPTP-induced Parkinson's Disease (PD) mouse model to establish in vivo proof-of-concept study to demonstrate that administration of LV-dCas9-DNMT3A virus can prevent and/or delay PD and test the efficacy and safety of SLS-004. Subsequently, other pre-clinical models would be utilized to further validate the investigational product.

"We are extremely pleased to begin the in vivo target engagement study with SLS-004 at Duke as it builds onto the work we began in the spring focused on designing a vector capable of inducing and suppressing Parkinson's related phenotypes," said Raj Mehra Ph.D., Chairman and CEO of Seelos. "Initiating this next portion of the studies at Duke should help us further validate this approach in Parkinson's."

Seelos has also begun work on designing a vector capable of inducing and suppressing PD-related phenotypes by carrying a unit to overexpress the alpha-synuclein (-synuclein) protein and a unit to mediate inducible suppression of -synuclein. The process aims to create a next-generation suppressive unit, carrying a more effective effector molecule than previously used, in the form of DNA methyltransferase 3A and 3L (DNMT3A & L). This research may help to advance a potential novel, effective and precise tool for reversing SNCA pathologies that can provide a valuable new therapeutic strategy for treating PD.

About SLS-004

SLS-004 is a novel epigenome-editing approach to modulate expression of SNCA gene mediated by modification of DNA-methylation. SLS-004 utilizes an all-in-one lentiviral vector harboring dCas9-DNA methyltransferase 3A (DNMT3A) to enrich DNA-methylation within CpGs island at the SNCA intron 1 region. The system resulted in a precise and fine-tuned downregulation (30%) of SNCA overexpression in hiPSC-derived dopaminergic neurons from a PD patient with the triplication of the SNCA locus (SNCA-Tri). Most importantly, the reduction of SNCA expression mediated by the developed system was sufficient to ameliorate disease related cellular phenotypes. The in vitro studies achieved several key millstones including the establishment that DNA hypermethylation at SNCA intron 1 allows an effective and sufficient tight downregulation of SNCA expression levels and suggests the potential of this target sequence combined with the CRISPR-dCas9 technology as a novel epigenetic-based therapeutic approach for PD.

Forward Looking Statements

Statements made in this press release, which are not historical in nature, constitute forward-looking statements for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. These statements include, among others, those regarding the initiation of a proof-of-concept study to demonstrate whether administration of the LV-dCas9-DNMT3A virus can prevent and/or delay PD, the potential for the LV-dCas9-DNMT3A virus to prevent and/or delay PD, the efficacy and safety of SLS-004, the potential use of other pre-clinical models to validate SLS-004, the potential for the in vivo proof-of-concept study to validate the design of a vector capable of inducing and suppressing PD-related phenotypes, and the potential for Seelos' research to advance a novel, effective and precise tool for reversing SNCA pathologies. These statements are based on Seelos' current expectations and beliefs and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Risks associated with Seelos' business include, but are not limited to, the risk of not successfully executing its preclinical and clinical studies and not gaining marketing approvals for its product candidates, the risk that prior test results may not be replicated in future studies and trials, the risks that clinical study results may not meet any or all endpoints of a clinical study and that any data generated from such studies may not support a regulatory submission or approval, the risks associated with the implementation of a new business strategy, the risks related to raising capital to fund its development plans and ongoing operations, risks related to Seelos' current stock price, risks related to the global impact of COVID-19, as well as other factors expressed in Seelos' periodic filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, even if subsequently made available by us on our website or otherwise. We do not undertake any obligation to update, amend or clarify these forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

Contact Information:Anthony MarcianoHead of Corporate CommunicationsSeelos Therapeutics, Inc. (Nasdaq: SEEL)300 Park Ave., 12th FlNew York, NY 10022(646) 293-2136[emailprotected]www.seelostherapeutics.comhttps://twitter.com/seelostxhttps://www.linkedin.com/company/seelos

SOURCE Seelos Therapeutics, Inc.

Front Page

Visit link:
Seelos Therapeutics Announces Sponsored Research Agreement with Duke University for Gene Therapy Studies of SLS-004 in Parkinson's Disease -...

The global Cancer Gene Therapy Market is subject to the arrival of numerous trends in the industry, which in turn is influencing the overall growth of the market. The Cancer Gene Therapy Market survey report is a product of an exhaustive analysis concerning the latest trends in the Cancer Gene Therapy Market. The report contains the market definition, fundamental applications in the market, as well as the different manufacturing methods employed. Our market survey report estimates the current market valuation to be at Cancer Gene Therapy Market, and with the help of the industry variable, we have predicted the market valuation to be at Cancer Gene Therapy Market by the end of the forecast period 2020-2027. We also predict the CAGR growth that will be reached by the end of the forecast period.

The major vendors covered: Bluebird bio, Inc., Merck, Adaptimmune, GlaxoSmithKline, Anchiano Therapeutics, Shenzhen SiBiono GeneTech, SynerGene Therapeutics, Celgene, Shanghai Sunway Biotech, OncoGenex Pharmaceuticals, and more

Get a free sample copy @ https://www.datalibraryresearch.com/sample-request/cancer-gene-therapy-market-2470?utm_source=thedailychronicle&utm_medium=39

Through our research, we aim to first introduce the reader to the market and inform them about the different areas of growth within the industry. This will include the different segments by which the Cancer Gene Therapy Market is divided, as well as a thorough regional analysis of the market. The market is segmented based on the product type, application, distribution channel, and region. Based on these different factors, we seek to understand the ability of the market to grow over the forecast period. We take into consideration the different socio-economic, political, and environmental fluctuations that could impact the overall growth of the market. Our Cancer Gene Therapy Market survey report provides a detailed and in-depth understanding of the industry and will help in understanding the business climate in a much better way.

Drivers and Risks

Through our report, we provide the readers with an understanding of the main drivers of the Cancer Gene Therapy Market. This includes a detailed analysis of the factors that create demand and the reasons for the same. We also delve into the many risks that are faced by the market, and how these play an important role in inhibiting the growth of the market.

Regional Description

After a general global overview of the Cancer Gene Therapy Market, we segment the market based on regions in order to better understand the different factors that drive the growth in these areas. Our Cancer Gene Therapy Market survey report includes North America, South America, Europe, Asia Pacific, Middle East, and Africa. We study the different trends in these regions and also analyse the reason why some regions are able to assert more dominance with regards to market share. We can also ascertain the different opportunities that could benefit the market in the long run.

Method of Research

Our Cancer Gene Therapy Market research methodology involves an analysis of the market during the forecast period with the help of the various parameters provided by Porters Five Force Model. A SWOT based analysis helps to further examine the main strengths, weaknesses, risks, and opportunities that are prevalent in the market, in order to give an in-depth understanding of the markets growth trajectory.

Key Players

Throughout our report, we give attention to the key players involved in the Cancer Gene Therapy Market. We discuss the market shares held by these companies and also try to understand their business operations influence on the Cancer Gene Therapy Market. We also keep the readers updated with the latest newsfrom the industry, including important partnerships and acquisitions.

If you have any special requirements about Cancer Gene Therapy Market report, please let us know and we can provide custom report.

Inquire more about this report @ https://www.datalibraryresearch.com/enquiry/cancer-gene-therapy-market-2470?utm_source=thedailychronicle&utm_medium=39

About Us:

Data Library Research is a market research company that helps to find its passion for helping brands grow, discover, and transform. We want our client to make wholehearted and long term business decisions. Data Library Research is committed to deliver their output from market research studies which are based on fact-based and relevant research across the globe. We offer premier market research services that cover all industries verticals, including agro-space defense, agriculture, and food, automotive, basic material, consumer, energy, life science, manufacturing, service, telecom, education, security, technology. We make sure that we make an honest attempt to provide clients an objective strategic insight, which will ultimately result in excellent outcomes.

Contact Us:

Alex Pandit,Senior Manager International Sales and MarketingData Library Research[emailprotected]Ph: +13523530818 (US)www.datalibraryresearch.com

Go here to see the original:
Cancer Gene Therapy Market Research 2020 to 2027| Post Impact of Worldwide COVID-19 Spread Analysis- Bluebird bio, Inc., Merck, Adaptimmune,...

TipRanks

Markets are volatile, there can be no doubt. So far this month, the S&P 500 has fallen 9% from its peak. The tech-heavy NASDAQ, which had led the gainers all summer, is now leading the on the fall, having lost 11% since September 2. The three-week tumble has investors worried that we may be on the brink of another bear market.The headwinds are strong. The usual September swoon, the upcoming election, doubts about another round of economic stimulus all are putting downward pressure on the stock markets.Which doesnt mean that there are no opportunities. As the old saw goes, Bulls and bears can both make money, while the pigs get slaughtered. A falling market may worry investors, but a smart strategy can prevent the portfolio from losing too much long-term value while maintaining a steady income. Dividend stocks, which feed into the income stream, can be a key part of such a strategy.Using the data available in the TipRanks database, weve pulled up three stocks with high yields from 7% to 11%, or up to 6 times the average dividend found on the S&P 500 index. Even better, these stocks are seen as Strong Buys by Wall Streets analysts. Lets find out why.Williams Companies (WMB)We start with Williams Companies, an Oklahoma-based energy company. Williams controls pipelines connecting Rocky Mountain natural gas fields with the Pacific Northwest region, and Appalachian and Texan fields with users in the Northeast and transport terminals on the Gulf Coast. The companys primary operations are the processing and transport of natural gas, with additional ops in crude oil and energy generation. Williams handles nearly one-third of all US commercial and residential natural gas use.The essential nature of Williams business really, modern society simply cannot get along without reliable energy sources has insulated the company from some of the economic turndown in 1H20. Quarterly revenues slid from $2.1 billion at the end of last year to $1.9 billion in Q1 and $1.7 billion in Q2. EPS in the first half was 26 cents for Q1 and 25 cents for Q2 but this was consistent with EPS results for the previous three quarters. The generally sound financial base supported the companys reliable dividend. Williams has been raising that payment for the past four years, and even the corona crisis could not derail it. At 40 cents per common share, the dividend annualizes to $1.60 and yields an impressive 7.7%. The next payment is scheduled for September 28.Truist analyst Tristan Richardson sees Williams as one of the midstream sectors best positioned companies.We continue to look to WMB as a defensive component of midstream and favor its 2H prospects as broader midstream grasps at recovery Beyond 2020 we see the value proposition as a stable footprint with free cash flow generation even in the current environment. We also see room for incremental leverage reduction throughout our forecast period on scaled back capital plans and even with the stable dividend. We look for modestly lower capex in 2021, however unlike more G&P oriented midstream firms, we see a project backlog in downstream that should support very modest growth, Richardson noted.Accordingly, Richardson rates WMB shares as a Buy, and his $26 price target implies a 30% upside potential from current levels. (To watch Richardsons track record, click here)Overall, the Strong Buy analyst consensus rating on WMB is based on 11 Buy reviews against just a single Hold. The stocks current share price is $19.91 and the average price target is $24.58, making the one-year upside potential 23%. (See WMB stock analysis on TipRanks)Magellan Midstream (MMP)The second stock on our list is another midstream energy company, Magellan. This is another Oklahoma-based firm, with a network of assets across much of the US from the Rocky Mountains to the Mississippi Valley, and into the Southeast. Magellans network transports crude oil and refined products, and includes Gulf Coast export shipping terminals.Magellan's total revenues rose sequentially to $782.8 in Q1, and EPS came in at $1.28, well above the forecast. These numbers turned down drastically in Q2, as revenue fell to $460.4 million and EPS collapsed to 65 cents. The outlook for Q3 predicts a modest recovery, with EPS forecast at 85 cents. The company strengthened its position in the second quarter with an issue of 10-year senior notes, totaling $500 million, at 3.25%. This reduced the companys debt service payments, and shored up liquidity, making possible the maintenance of the dividend.The dividend was kept steady at $1.0275 per common share quarterly. Annualized, this comes to $4.11, a good absolute return, and gives a yield of 11.1%, giving MMP a far higher return than Treasury bonds or the average S&P-listed stock.Well Fargo analyst Praneeth Satish believes that MMP has strong prospects for recovery. [We] view near-term weakness in refined products demand as temporary and recovering. In the interim, MMP remains well positioned given its strong balance sheet and liquidity position, and ratable cash flow stream Satish goes on to note that the dividend appears secure for the near-term: The company plans to maintain the current quarterly distribution for the rest of the year.In line with this generally upbeat outlook, Satish gives MMP an Overweight (i.e. Buy) rating, and a $54 price target that implies 57% growth in the coming year. (To watch Satishs track record, click here)Net net, MMP shares have a unanimous Strong Buy analyst consensus rating, a show of confidence by Wall Streets analyst corps. The stock is selling for $33.44, and the average price target of $51.13 implies 53% growth in the year ahead. (See MMP stock analysis on TipRanks)Ready Capital Corporation (RC)The second stock on our list is a real estate investment trust. No surprise finding one of these in a list of strong dividend payers REITs have long been known for their high dividend payments. Ready Capital, which focuses on the commercial mortgage niche of the REIT sector, has a portfolio of loans in real estate securities and multi-family dwellings. RC has provided more than $3 billion in capital to its loan customers.In the first quarter of this year, when the coronavirus hit, the economy turned south, and business came to a standstill, Ready Capital took a heavy blow. Revenues fell by 58%, and Q1 EPS came in at just one penny. Things turned around in Q2, however, after the company took measures including increasing liquidity, reducing liabilities, and increasing involvement in government-sponsored lending to shore up business. Revenues rose to $87 million and EPS rebounded to 70 cents.In the wake of the strong Q2 results, RC also started restoring its dividend. In Q1 the company had slashed the payment from 40 cents to 25 cents; in the most recent declaration, for an October 30 payment, the new dividend is set at 30 cents per share. This annualizes to $1.20 and gives a strong yield of 9.9%.Crispin Love, writing from Piper Sandler, notes the companys success in getting back on track.Given low interest rates, Ready Capital had a record $1.2B in residential mortgage originations versus our $1.1B estimate. Gain on sale margins were also at record levels. We are calculating gain on sale margins of 3.7%, up from 2.4% in 1Q20, Love wrote.In a separate note, written after the dividend declaration, Love added, We believe that the Board's actions show an increased confidence for the company to get back to its pre-pandemic $0.40 dividend. In recent earnings calls, management has commented that its goal is to get back to stabilized earnings above $0.40, which would support a dividend more in-line with pre-pandemic levels.To this end, Love rates RC an Overweight (i.e. Buy) along with a $12 price target, suggesting an upside of 14%. (To watch Loves track record, click here)All in all, Ready Capital has a unanimous Strong Buy analyst consensus rating, based on 4 recent positive reviews. The stock has an average price target of $11.50, which gives a 9% upside from the current share price of $10.51. (See RC stock analysis on TipRanks)To find good ideas for dividend stocks trading at attractive valuations, visit TipRanks Best Stocks to Buy, a newly launched tool that unites all of TipRanks equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

The rest is here:
PTC Therapeutics to Present at the Jefferies Virtual Gene Therapy/Editing Summit - Yahoo Finance

This press release was orginally distributed by SBWire

Albany, NY -- (SBWIRE) -- 09/25/2020 -- Transparency Market Research (TMR) has published a new report titled, "Gene Therapy Market Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 20182026". According to the report, the global gene therapy market was valued at US$ 17.0 Mn in 2017 and is projected to expand at a CAGR of 40.0% from 2018 to 2026. New product approvals, promising therapeutic outcomes of gene therapy, and high prevalence of non-Hodgkin Lymphoma are anticipated to drive the global market in the next few years. Europe is projected to dominate the global gene therapy market, followed by U.S., by the end of 2026.

Potential unmet needs in the fields of oncology, rare genetic disorders in the U.S. and Europe, new product approvals and commercialization, and high clinical R&D budgets are likely to drive the gene therapy market in these regions during the forecast period. The gene therapy market in Rest of World is projected to expand at a significant CAGR during the forecast period. The high growth rate is attributed to the anticipated approval and commercialization of gene therapy products in developed countries such as Japan, Australia & New Zealand, GCC countries, and China, and high prevalence of non-Hodgkin Lymphoma and head and neck cancers.

View Report : https://www.transparencymarketresearch.com/gene-therapy-market.html

gene therapy marketNew product approvals & commercialization drives market

2016, 2017, and 2018 were key milestones in the history of the gene therapy market in the U.S. and Europe, as around four gene therapy products have been approved and commercialized. These products are currently in the infancy stage of commercialization, and have exhibited highly positive therapeutic outcomes.

Get PDF Sample Copy of Report: (Including TOC, List of Tables & Figures, Chart) : https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=60429

For instance, in May 2016, GlaxoSmithKline (GSK) gene therapy product, Strimvelis, received marketing approval for the treatment of patients with a very rare disease called ADA-SCID (Severe Combined Immunodeficiency, due to Adenosine Deaminase deficiency). Strimvelis is the first ex-vivo stem cell gene therapy to be approved in Europe for the treatment of ADA-SCID. Furthermore, in August 2017, the USFDA approved Novartis AG's flagship gene therapy product, Kymriah, for the treatment of children and adults up to the age of 25 years affected with B-cell precursor acute lymphoblastic leukemia (ALL). Thus, recent approvals of gene therapy products in the U.S. and Europe for the treatment of various life threatening disorders is projected to fuel the gene therapy market during the forecast period.

Yescarta to be highest revenue generating gene therapy product

The report offers a detailed segmentation of the global gene therapy market based on different gene therapy products approved and commercialized. Based on product, the global gene therapy market has been segmented into Yescarta, Kymriah, Luxturna, Strimvelis, and Gendicine. Yescarta (Axicabtagene Ciloleucel) is a genetically modified autologous Chimeric Antigen Receptor T (CAR T) cell immunotherapy developed by Gilead Sciences, Inc. for the treatment of adult patients with relapsed or refractory large B-cell lymphoma including diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL). It is the first CAR T therapy approved by the US FDA for the treatment of DLBCL. The Yescarta segment is projected to dominate the global gene therapy market by the end of 2026. Anticipated commercialization of Yescarta in Europe and other developed countries and increasing number of treatment centers are key factors that are likely to lead to the dominant share held by Yescarta by the end of 2026.

REQUEST FOR COVID19 IMPACT ANALYSIS https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=1838

Oncology segment to account for high market share

In terms of application, the global gene therapy market has been segmented into ophthalmology, oncology, and adenosine deaminase ?deficient severe combined immunodeficiency (ADA-SCID). The oncology segment is likely to account for a significant share of the market by the end of 2026. Oncology is a highly studied medical field in the clinical pipeline studies of gene therapy candidates. More than 60% of gene therapy clinical research studies are focused on oncology. The large share held by the oncology segment is attributed to the approval and commercialization of Yescarta and Kymriah, in the last one to two years, for the treatment of certain types of non-Hodgkin lymphoma in the U.S. and Europe. Furthermore, increase in demand for Gendicine in China for the treatment of head and neck cancers is projected to drive the segment during the forecast period.

Europe offers high incremental opportunity

The gene therapy market in Europe is projected to expand at a significant CAGR of 30.6% during the forecast period. Large number of patient population with refractory large B-cell lymphoma, including diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL), promising therapeutic outcomes, rising demand for gene therapy treatment, and increasing number of gene therapy treatment centers in Europe are key factors that are likely to fuel the gene therapy market in Europe. Moreover, different pricing models are being evaluated by payers and governments to enable access to high priced gene therapy products. This is likely to drive the demand for gene therapy products in Europe during the forecast period.

Read our Case study at : https://www.transparencymarketresearch.com/casestudies/innovative-medical-device-manufacturing-start-up

Large number of clinical pipeline studies and significant investments in gene therapy to gain the first mover advantage

The global gene therapy market is highly consolidated, with very few global players accounting for a major share. Currently, only five companies; Gilead life Sciences Inc. Spark Therapeutic Inc., Novartis AG, Sibiono GeneTech Co. Ltd, and Orchard Therapeutics Limited offer gene therapy products in the market. Most biopharmaceutical companies have invested significantly in clinical R&D for the development of gene therapy products for different chronic and genetic disorders. Large number of gene therapy products are under different stages of clinical pipeline studies, and the number of gene therapy candidates is projected to rise consistently during the forecast period. For instance, according to the Journal of Gene Medicine, there were around 2,597 gene therapy candidates under clinical trials, as of 2017. Of the total clinical studies, around 65% of studies were focused on oncology, 11% of studies were focused on monogenetic field, 7% on infectious diseases and cardiovascular disease, each.

More Trending Reports by Transparency Market Research 1. http://www.prnewswire.com/news-releases/despite-several-factors-supporting-osteoporosis-drugs-market-patent-expiration-of-blockbuster-drugs-to-hamper-markets-progress-tmr-301019711.html

2. https://www.biospace.com/article/3d-applications-in-health-care-market-applications-of-3d-printing-technology-to-disrupt-paradigms-in-healthcare-services-and-medicine-tmr/

For more information on this press release visit: http://www.sbwire.com/press-releases/gene-therapy-market/release-1306012.htm

Here is the original post:
Gene Therapy Market Trends by Manufacturers, States, Type and Application - Press Release - Digital Journal

Overview Of Gene Therapy Industry 2020-2025:

This has brought along several changes in This report also covers the impact of COVID-19 on the global market.

The Gene Therapy Market analysis summary by Reports Insights is a thorough study of the current trends leading to this vertical trend in various regions. Research summarizes important details related to market share, market size, applications, statistics and sales. In addition, this study emphasizes thorough competition analysis on market prospects, especially growth strategies that market experts claim.

Gene Therapy Market competition by top manufacturers as follow:Kite PharmaBioVexNovartisSpark Therapeutics

Get a Sample PDF copy of the report @ https://reportsinsights.com/sample/7583

The global Gene Therapy market has been segmented on the basis of technology, product type, application, distribution channel, end-user, and industry vertical, along with the geography, delivering valuable insights.

The Type Coverage in the Market are: Ex VivoIn Vivo

Market Segment by Applications, covers:Cancer DiseasesHematological DiseaseHereditary DiseaseOthers

Market segment by Regions/Countries, this report coversNorth AmericaEuropeChinaRest of Asia PacificCentral & South AmericaMiddle East & Africa

Major factors covered in the report:

To get this report at a profitable rate.: https://reportsinsights.com/discount/7583

The analysis objectives of the report are:

Access full Report Description, TOC, Table of Figure, Chart, [emailprotected] https://reportsinsights.com/industry-forecast/Gene-Therapy-Market-7583

About US:

Reports Insights is the leading research industry that offers contextual and data-centric research services to its customers across the globe. The firm assists its clients to strategize business policies and accomplish sustainable growth in their respective market domain. The industry provides consulting services, syndicated research reports, and customized research reports.

Contact US:

:(US) +1-214-272-0234

:(APAC) +91-7972263819

Email:[emailprotected]

Sales:[emailprotected]

Read the original:
Gene Therapy Market: Technological Advancement & Growth Analysis with Forecast to 2025 - The Daily Chronicle

LEXINGTON, Mass., Sept. 25, 2020 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a genome editing company focused on developing medicines to durably treat rare diseases in pediatric patients, today announced CEO Fred Chereau will present at the Jefferies Virtual Gene Editing/Therapy Summit on Friday, October 2, 2020 at 11:30 AM, ET.

A live audio webcast of the presentation will be available under the Events and Presentations section of LogicBios website. A replay of the presentation will become available approximately one hour after the event and will be archived for 30 days.

About LogicBio Therapeutics

LogicBio Therapeutics is a genome editing company focused on developing medicines to durably treat rare diseases in pediatric patients with significant unmet medical needs using GeneRide, its proprietary technology platform. GeneRide enables the site-specific integration of a therapeutic transgene in a nuclease-free and promoterless approach by relying on the native process of homologous recombination to drive potential lifelong expression. Headquartered in Lexington, Mass., LogicBio is committed to developing medicines that will transform the lives of pediatric patients and their families. For more information, please visit http://www.logicbio.com

Contacts:

Investors:Matthew Lane

Gilmartin Investor Relation

matt@gilmartinir.com

Media:Stephanie Simon

TenBridge Communications

Stephanie@tenbridgecommunications.com

617-581-9333

Read more from the original source:
LogicBio Therapeutics to Present at the Jefferies Virtual Gene Editing/Therapy Summit October 2, 2020 - GlobeNewswire

DetailsCategory: DNA RNA and CellsPublished on Friday, 25 September 2020 11:52Hits: 367

Focus on effect of SVecTM on downregulation of pathological immune responses underlying the destruction of own cells in DM1 and in MS patients

Investment of 0.6 million (US$0.7 million) in animal proof-of-principle studies

LEIDEN, The Netherlands and SEVILLE, Spain I September 25, 2020 I Amarna Therapeutics, a Dutch privately held biotechnology company developing the next-generation SV40-based gene delivery vector platform transforming gene-replacement and immunotherapy across many disease areas. The company today announced it has entered into a collaboration with scientists from the Progreso y Salud Foundation (FPS) at Cabimer in Seville, to jointly examine the efficacy of Amarnas SVecTM gene delivery vector to develop effective immunotherapies for diabetes mellitus type 1 (DM1) and multiple sclerosis (MS).

The collaboration is a joint effort between the research group of the FPS at research institute Cabimer, led by Dr. Benoit Gauthier, and Amarna Therapeutics, represented by Dr. Peter de Haan (CSO) and Miguel Garca Toscano (Head of Laboratory in Spain).

To date, the symptoms of DM1 and MS can be managed, but patients cannot be cured from both autoimmune diseases. The aim of this joint effort is to study the efficacy of Amarnas SV40-based gene delivery vector platform, denoted SVecTM, for downregulation of pathological immune responses that underlie the destruction of own cells in DM1 and in MS patients.

The research will focus on the induction of SVecTM-mediated immune tolerance to the primary self-antigens of both diseases. The studies will use advanced animal models of both autoimmune diseases, that have been established by the collaboration partners. Amarna will invest some 0.6 million over the next two years in the Gauthier research group to conduct the animal proof-of-principle studies for these two indications, for which at present there are no cures available.

Benoit Gauthier, Staff Scientist at Junta de Andalucia-Consejeria de Salud y Familias, comments:

We are thrilled to start this new venture with Amarna Therapeutics, a world leader in viral gene therapy and we anticipate the studies to generate exciting results

Peter de Haan, Amarna Therapeutics Chief Scientific Officer, adds:

We are delighted entering this collaboration with such a renowned academic partner like FPS and we look very much forward to initiate the planned studies. Since the quality of life for patients with DM1 and MS is so severely impaired given the lack of cures for these invalidating diseases, the more efficiently we can develop our groundbreaking SV40-based gene delivery vector based therapies, the sooner patients will experience the positive impact of our solution on their lives.

About FPS

For more than ten years, Benoit Gauthier's research group has focused on the field of diabetes and recently other autoimmune diseases. Its basic quality research has generated important new knowledge which enable the development of new therapies for this disease cluster. An important finding of the group was the mandatory association of immune responses to pancreatic beta cells with their capacity to regenerate in patients with type 1 diabetes. In addition, the discovery of the PAX8 gene, and the relationship between type 2 diabetes (T2D) and increased risk of pancreatic cancer, led to international recognition and generated numerous publications in peer-reviewed scientific journals.

The group is funded by different national and international public and private institutions, as well as from diabetes patient associations and supported by the Andalusian Government.

Amarna Therapeutics

Amarna Therapeutics is a privately held Biotech company founded in 2008. Its head office is located in Leiden (The Netherlands), and it also holds a research facility in Seville (Spain). The company has developed a proprietary production and gene therapy delivery platform in its SuperVeroTM cell line and SVecTM vector for the development of safe and efficient therapies. The companys pipeline targets several major indications as well as orphan diseases within the field of degenerative, inflammatory and autoimmune diseases. The company plans to take the first candidate from its pipeline into clinical development in 2021.

In October 2019, Amarna secured 10 million in new equity, with the aim of bringing the first product into clinical studies. The financing round was led by the Swedish Flerie Invest AB, together with existing shareholders and an innovation credit from the Netherlands Enterprise Agency (RVO.nl).

SOURCE: Amarna Therapeutics

Link:
Dutch Amarna Therapeutics enters research collaboration with Spanish FPS, examining the efficacy of its SV40-based SVecTM gene delivery vector...

Diabetes is a chronic condition that affects how your body uses insulin. This hormone controls how much blood sugar, also known as glucose, is released into your cells to be used as energy.

Over 34 million people in the US have diabetes, according to the Centers for Disease Control and Prevention (CDC). While there is no cure for diabetes, it can be managed with lifestyle and dietary changes, or medication like insulin.

Here's what you need to know to manage diabetes and lower blood sugar levels.

With all types of diabetes, your body either doesn't produce enough insulin, or isn't able to use insulin effectively.

Insulin is necessary to move blood sugar into your cells, where it is stored and used for energy. Without insulin, a condition called hyperglycemia can occur, where blood sugar builds up in your bloodstream instead of traveling into your cells.

Type 1 diabetes makes up just 10% of all diagnosed diabetes cases in the US, according to the CDC. It is most commonly diagnosed in children, teenagers, and young adults.

Although the cause is unknown, type 1 diabetes may be due to an autoimmune response caused by an infection or other trigger. Your body mistakenly attacks and damages the beta cells in your pancreas that make insulin, so little or no insulin is produced.

There are not many risk factors for type 1 diabetes, though genetics is believed to play a role. The odds of the children of men with type 1 diabetes developing the condition is 1 in 17, according to the American Diabetes Association (ADA). For the children of women with type 1 diabetes, the odds are 1 in 25 if the woman is under the age of 25, or 1 in 100 after the age of 25.

A type 1 diabetes diagnosis requires some important lifestyle changes. You must take insulin every day in order to survive. Your blood sugar level needs to be frequently monitored. It's essential to carefully plan your meals and count carbohydrates.

"This can be a frustrating and tiresome adjustment, but it is crucial that patients educate themselves on how certain foods impact glucose levels," says endocrinologist Rocio Salas-Whalen, MD, of New York Endocrinology.

Type 2 diabetes makes up about 90% of all diagnosed diabetes cases in the US. It is most often diagnosed in adults, but the CDC notes that it is becoming increasingly diagnosed in children and teenagers.

With type 2, your body can produce insulin, but it is not able to use it effectively. This is called insulin resistance, which happens when your liver, muscle, and fat cells don't effectively take in the blood sugar from your blood to use it for energy. As a result, your blood sugar level increases, which can eventually lead to type 2 diabetes.

You are more at risk for type 2 diabetes if you:

In addition to eating a healthy diet, it's very important for people with type 2 diabetes to maintain a healthy weight, Salas-Whalen says, because this can also help them control blood sugar levels.

Pregnant people may develop gestational diabetes, which is caused by the body's inability to produce the extra insulin needed during your pregnancy. Gestational diabetes can put your baby at risk for health problems later in life, such as obesity or type 2 diabetes.

About 7% of pregnant people in the US are diagnosed with gestational diabetes. It usually begins in the middle of your pregnancy, without any symptoms. You should be tested for it between your 24th and 28th weeks of pregnancy. It typically goes away after your baby is born, but you will have a higher risk of developing type 2 diabetes later in life.

If you have gestational diabetes, you'll need to work with your doctor to develop a healthy eating plan, and you should also remain physically active to help keep your blood sugar levels low. If a healthy diet and exercise don't lower your blood sugar levels, you may need to take insulin.

Prediabetes is a condition where your blood sugar levels are elevated, but not yet high enough for a diabetes diagnosis. However, if left untreated, prediabetes can develop into type 2 diabetes.

More than a third of all US adults over 88 million have prediabetes, yet 84% of them don't know they have it, the CDC notes.

With lifestyle changes like a healthy diet, losing weight, and getting regular exercise, it's possible for prediabetes to be reversed or delayed. Your doctor may also prescribe medication to help lower your blood sugar level.

"A prediabetic still has the potential to avoid diabetes, which should be avoided in every possible way," Salas-Whalen says.

The signs of all types of diabetes can include the following:

However, these symptoms develop slowly over time, and it may be difficult to recognize them, especially if you have type 2 diabetes. The signs of type 1 diabetes may be more severe, and can also include nausea or vomiting.

Target blood sugar levels are different for those with diabetes. The follow chart depicts normal blood sugar levels for diabetics and non-diabetics:

Yuqing Liu/Insider

Many people with diabetes with need to learn how to check their blood sugar multiple times a day using a glucose meter or a continuous glucose meter.

"Try not to think of blood sugars as 'good' or 'bad' or as a reflection of how well or bad you are doing," says Shelley Nicholls, DNP, APRN, CDCES, director of patient education at the Diabetes Research Institute. "Having a good understanding of what affects blood sugars and which of them a person can control or influence is the best tool a person with diabetes can have."

To treat diabetes, it is important to lower your blood sugar level and make sure it stays in a healthy range.

Doing this will not only increase your energy, but according to the ADA, each percentage point of A1C lowered reduces the possibility of long-term health complications which could include serious heart, kidney, brain, eye, or foot problems by 40%.

These are some of the best natural ways to lower and manage your blood sugar levels over time:

It's important for people with diabetes to be careful about the foods they eat because they can impact your blood sugar levels."Some foods can worsen diabetes, while other foods can actually improve diabetes control," Salas-Whalen says.

Carbohydrates and fiber especially affect your blood sugar levels in the following ways:

It can be helpful to follow a diet to manage your diabetes, as planning out your meals and snacks will help you control blood sugar levels effectively.

"Every person has different needs, so there is no one diet that is recommended for people with diabetes," Nicholls says. "The best option is to meet with a dietitian to determine individual needs and goals."

Here are some of the best diets for diabetics:

The Mediterranean diet includes plant-based foods, lean meats, and healthy fats.

According to a 2009 study published in Diabetic Medicine, people who strictly followed a Mediterranean diet for three months had lower A1C percentages and lower blood sugar levels after meals than those who followed it less strictly.

The DASH diet, which stands for Dietary Approaches to Stop Hypertension, is mainly used to lower blood pressure, but it can also help lower blood sugar.

A 2017 study published in the ADA journal Diabetics Spectrum suggests that the DASH diet can lower insulin resistance and help you lose weight. A 2016 study published in the journal Nutrition found that a DASH diet can also help lower the risk for gestational diabetes by as much as 71%.

This high-fat, low-carb diet limits carbs to 20 to 50 grams daily in an effort to put your body in the metabolic state of ketosis, where you burn fat instead of carbs for fuel.

A 2017 study published in Nutrition & Diabetes found that overweight adults with type 2 diabetes or prediabetes who followed a keto diet had lower A1C levels and lost over 4% more weight after one year than those who followed a moderate-carbohydrate/low-calorie/low-fat diet.

There are also some health risks associated with the keto diet. If you have type 1 diabetes, your lowered blood sugar level may lead to hypoglycemia and serious brain, kidney, or liver complications.

Another issue associated with this diet are "keto flu" symptoms that may include headache, nausea, and vomiting. It's important to consult with your doctor or a registered dietitian before starting a keto diet.

People with type 1 diabetes need to take insulin every day in order to survive. If people with type 2 diabetes are unable to reach their blood sugar target levels with diet and exercise, they may also need medication like insulin or metformin.

People with type 1 diabetes generally need to take three to four doses of insulin every day, according to the ADA. Women with gestational diabetes may need to take insulin daily during their pregnancy if their bodies aren't producing enough of it naturally. Many people with type 2 diabetes may need one dose each day with or without other medications.

Insulin is injected in the fat under your skin using a syringe, insulin pen, or pump. It should be injected in the same area of the body, but not the same place each day. It's best to inject insulin at mealtime so it is more effectively processed in your body.

There are many different types of insulin, and your doctor may even prescribe two or more of the following types:

"The challenge with taking insulin is that it's tough to know precisely how much to take," Nicholls says. The amount is based on factors that may change throughout the day, such as food, exercise, and stress. "So, deciding on what dose of insulin to take is a complicated balancing act."

Taking an extra dose of insulin can also help you lower blood sugar fast if it's an emergency, though you may want to check in with your doctor beforehand.

If you have type 2 diabetes, your doctor may prescribe metformin, a medication that lowers blood sugar by slowing your liver's production of glucose. It is the drug most commonly prescribed to treat type 2 diabetes.

Metformin is available in a liquid, pill, or extended-release tablet. You take it orally at mealtime two to three times a day. The extended-release tablet only needs to be taken once daily.

According to a 2012 scientific review published in Diabetes Care, metformin can effectively reduce A1C levels for people with type 2 diabetes by an average of 1.12%.

Although it's possible to control your diabetes and lower blood sugar levels, there is no specific cure.

"Because of this reality, lifestyle changes must be permanent and not temporary in order to avoid the potential long-term complications of diabetes," Salas-Whalen says.

To develop the best plan of treatment for diabetes, it's important to meet with your doctor for individualized recommendations.

Link:
What is diabetes? A comprehensive guide to lower blood sugar and manage the condition - Insider - INSIDER

September 25, 2020 -A group of Senators has introduced a bill that would expand access to the Medicare Diabetes Prevention Program through telehealth.

S 4709 was introduced this week by Senators Tim Scott (R-SC), Mark warner (D-VA), Kevin Cramer (R-ND), Kyrsten Sinema (D-AZ), Tom Cotton (R-AR) and Tina Smith (D-MN). Titled the Prevent Diabetes Act, it addresses a long-standing issue with a Medicare program designed to help members at increased risk of developing type 2 diabetes.

Its no secret that diabetes is a disease that has disproportionately affected minority communities across the country, Warner said in a press release. To ensure that all individuals have the tools needed to combat this preventable disease, the Prevent Diabetes Act would help expand access to virtual classes under the existing Medicare Diabetes Prevention Program. This commonsense and cost-saving expansion will ensure that more Americans at-risk of developing diabetes who are living in either rural or medically underserved communities, can participate in this critical program that has been proven to delay the full onset of this preventable disease.

The original Diabetes Prevention Programwas developed by the National Institutes of Healths National Institute of Diabetes and Digestive and Kidney Disease (NIDDK), and focused on in-person classes and one-on-one coaching. Based on that model, which is administered by the Centers for Disease Control and Prevention, the Centers for Medicare & Medicaid Services created the National Diabetes Prevention Program for Medicare beneficiaries and launched that program in 2018.

But the Medicare Diabetes Prevention Program Expanded Model conducted by the Center for Medicare and Medicaid Innovation doesnt reimburse care providers for using connected health platforms. Telehealth and mHealth advocates have been lobbying for years to add those services, saying a virtual platform would reach far more people at risk and enable providers to make better use of limited resources.

More than 70 healthcare providers are now listed on the CDCs DPP website, though only a handful have been recognized as offering proof that their online programs reach recognized benchmarks for activity and weight loss.A growing number of programs are using virtual careas a means of expanding the programs reach and making the most of limited resources, and theyre asking CMS to cover those services.

Last year, a group of Senators including those sponsoring the Prevent Diabetes Act wrote a letter to Health and Human Services Secretary Alex Azar and CMS Administrator Seema Verma asking that the program be expanded to include CDC-recognized virtual DPP providers.

Virtual delivery of MDPP has the ability to empower beneficiaries to access MDPP regardless of where they live, and in the format of their choosing, the Senators wrote. Because of the outcome-focused reimbursement structure, CMS has insulated from reimbursing for ineffective treatment. Medicare Advantage plans have also been vocal in their desire to deploy virtual DPP for their beneficiaries. Given this, we also encourage CMS to consider ways for Medicare Advantage plans to use virtual providers to ensure that all Medicare beneficiaries have access to a CDC fully-recognized DPP.

In April, that same group lobbied again for the inclusion of virtual care providers, saying the coronavirus pandemic has created further barriers to in-person care.

The new bill, which as of September 25 contains no text or summary, is supported by several organizations, including the American Diabetes Association, American Medical Association, Connected Health Initiative and National Kidney Foundation, along with digital health companies Livongo, Noom and Omada Health.

More:
New Bill Would Add Telehealth to Medicare Diabetes Prevention Program - mHealthIntelligence.com

Frequent hot tub bathinghada positive impact on glycemia, blood pressure, and body weight in patients with type 2 diabetes, in the first real-world study to analyze the effect of this type of heat therapy in such individuals.

"The data from our analysis showed that the frequency of hot tub bathing could have beneficial influences on diabetic control, hypertension, and obesity even after adjusting for confounding factors," HisayukiKatsuyama, MD, told Medscape Medical News.

Katsuyama presented the findings as a poster at the virtual European Association for the Study of Diabetes (EASD) Annual Meeting 2020. The study aimed to explore the real-world influence of habitual hot tub bathing on the control of type 2 diabetes and other cardiovascular risk factors.

"Heat therapy, shown here with hot tub bathing, can be one effective therapeutic option for type 2 diabetes in daily life. An alternative form of heat exposure might be nutrition therapy and exercise," noted Katsuyama, from Kohnodai Hospital, Ichikawa, Chiba, Japan.

But Lucy Chambers, PhD, head of research communications at Diabetes UK, was not so enthusiastic about the results.

"While this research suggests there might a link between taking regular hot baths and better health in people with type 2 diabetes, it raises more far more questions than it answers," she said.

"It could be that people who bathe more frequently have a healthier lifestyle in general perhaps they are more physically active we just don't know from the limited data collected."

"It isnot possible to say from this research whether bathingcan benefit yourphysicalhealth," she noted in a statement from Diabetes UK.

Prior to the current study, there were no large studies looking at the effects of hot tub bathing on metabolic parameters in patients with diabetes.

One cohort study in Finland revealed that frequency of sauna bathing was inversely associated with fatal cardiovascular events in middle-aged adults (BMC Med. 2018;16:219). And a prior small before-and-after study in patients with diabetes showed a significant reduction in fasting glucose and A1c (N Engl J Med. 1999;341:924-925), Katsuyama noted.

Most homes in Japan, where bathing is a traditional and common practice, have hot tubs, which prompted the researchers' idea for a real-world study, he explained.

Katsuyama and colleagues studied the frequency of hot-tub bathing using a self-reported questionnaire completed by 1297 patients with type 2 diabetes who regularly visited Kohnodai Hospital over 6 months.

They took anthropometric measurements and used blood test results to analyze associations between hot tub use and different variables. Patients were divided into three groups according to frequency of bathing: group 1, 4 baths/week; group 2, 1-<4 baths/week; and group 3, < 1 bath/week.

Mean age was 67 years, weight was 67 kg, BMI was 25.9 kg/m2, and A1c was 7.2%. There were more men than women (713/584).

Most participants, 693, were in group 1 ( 4 baths/week), 415 were in group 2 (1-< 4 baths/week); and 189 were in group 3 (< 1 bath/week).

The mean frequency of bathing was 4.2 times/week and mean duration of bathing was 16 minutes.

Body weight, BMI, waist circumference, diastolic blood pressure, and A1c were all significantly better in group 1 (most frequent bathing) compared with group 3 (least frequent bathing) (Table).

Table. Effects of Frequency of Hot Tub Bathing on Metabolic Parameters

Group 1 4 baths/week

BP = blood pressure

Katsuyama pointed out that animal studies have suggested heat stimulation might improve insulin sensitivity and enhance energy expenditure, an effect also observed during exercise.

"I expect that patients can benefit in a similar way with heat therapy," he added, noting that hot tub bathing might be particularly beneficial for patients who cannot exercise.

"It would probably [also] be beneficial for the prevention of diabetes," and potentially, diabetes complications, he said. Indeed, "cohort studies have shown the possibilities that heat therapy could prevent cardiovascular diseases."

Katsuyama pointed out that a key strength of the study was the relatively large number of participants compared with previous studies.

But there were also limitations due to the nature of the cross-sectional study, which "means we cannot guarantee causality, and secondly, various confounding factors, such as diet and other life habits, could influence the results."

"A well-designed prospective study will be needed to confirm the beneficial effects of the heat therapy," he concluded.

EASD 2020. Presented September 22, 2020. Abstract 342.

Katsuyama has reported no relevant financial relationships.

For more diabetes and endocrinology news, follow us on Twitter and Facebook.

Read more here:
Hot Tubs Improve A1c, BMI, and Blood Pressure in Type 2 Diabetes - Medscape

Dublin, Sept. 25, 2020 (GLOBE NEWSWIRE) -- The "Worldwide Diabetes Reusable Insulin Delivery Pen Market: Demand, Insights, Trends, Analysis, Opportunities, Growth Potential and Forecast to 2026" report has been added to ResearchAndMarkets.com's offering.

The Worldwide Diabetes Reusable Insulin Delivery Pen Market size is expected to touch US$ 6 billion by 2026.

The report offers the most up-to-date industry data on the actual market situation and future outlook for the worldwide diabetes reusable insulin delivery pen market. The report provides historical market data for 2013 - 2019, and forecasts from 2020 until 2026.

The report contains a granular analysis of the present industry situations, market demands, reveal facts on the market size, reusable insulin pen volume, revenues for reusable insulin delivery pen, and illustrative forecast to 2026. It also provides 16 countries with an all-round analysis of an overall number of patients with diabetes and insulin users. A comprehensive analysis has been done on the market share of the countries-based market.

The report explores essential insights into worldwide diabetes reusable insulin delivery pen market for the top 16 countries, comprising the United States, the United Kingdom, Canada France, Italy, Spain, Germany, Netherlands, Poland, Sweden, Turkey, Australia, Japan, China, India, and Brazil until 2026. The report also provides a detailed description of growth drivers and inhibitors of the worldwide diabetes reusable insulin delivery pen market.

The report concludes with the profiles of major players in the worldwide diabetes reusable insulin delivery pen market. The key market players are evaluated on various parameters such as company overview, product portfolios and recent development of the worldwide diabetes reusable insulin delivery pen market

Key Questions Answered in this Market Research Report:

The Major Companies Dominating this Market for its Products, Services and Continuous Product Developments are:

Key Topics Covered:

1. Executive Summary

2. Diabetes Reusable (Cartridge) Insulin Delivery Pen Users (Volume), 2013 - 2026

3. Diabetes Reusable (Cartridge) Insulin Delivery Pen Market (Value), 2013 - 2026

4. Diabetes Reusable (Cartridge) Insulin Delivery Pen Market Share, By Users (%) 2013 - 2026

5. Diabetes Reusable (Cartridge) Insulin Delivery Pen Market Share (%), 2013 - 2026

6. Key Market Drivers & Inhibitors of the Diabetes Reusable (Cartridge) Insulin Delivery Pen Market6.1 Market Drivers6.2 Market Inhibitors

7. Diabetes Reusable (Cartridge) Insulin Delivery Pen Market & Forecast (2013 - 2026) - Major 16 Countries Data Analysis7.1 United States7.1.1 Overall Diabetes Population & Forecast (Volume) 7.1.2 Insulin Users & Forecast (Volume) 7.1.3 Diabetes Reusable (Cartridge) Insulin Delivery Pen Users (Volume) 7.1.4 Diabetes Reusable (Cartridge) Insulin Delivery Pen Market & Forecast (Value) 7.2 Canada7.3 Germany7.4 France7.5 Italy7.6 Spain7.7 United Kingdom7.8 Netherlands7.9 Poland7.10 Sweden7.11 Turkey7.12 Australia7.13 Japan7.14 China7.15 India7.16 Brazil

8. Key Companies Analysis8.1 Business Overview8.2 Insulin Pen Products Portfolio8.3 Recent Development

For more information about this report visit https://www.researchandmarkets.com/r/nmbp1s

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Visit link:
Worldwide Diabetes Reusable Insulin Delivery Pen Market Report 2020: Demand, Insights, Trends, Analysis, Opportunities, Growth Potential and Forecast,...

A leading manufacturer of automated insulin delivery systems, Dexcom (NASDAQ:DXCM) signed a five-year collaboration agreement with the University of Virginia on Thursday . The company will fund research at the university that could expand its addressable patient population.

Dexcom already has clinical trial evidence that shows its constant glucose monitoring (CGM) technology reduces the amount of time Type 1 diabetes patients spend with blood sugar levels that are too high or too low. Through its collaboration with the university, the company will test its CGM technology for use among people with Type 2 and gestational diabetes, as well as for hospitalized patients.

Image source: Getty Images.

The University of Virginia's Center for Diabetes Technology will lead the research efforts, but the collaboration will employ experts from multiple disciplines across the University of Virginia System.

This isn't the first time these two have conducted research as partners. In 2019, the collaboration partners presented successful results of a trial with Type 1 diabetes patients that used Dexcom's CGM technology to control their blood sugar levels.

In 2020, Dexcom expects revenue to grow by about 25% to around $1.85 billion. While there has been some uptake of Dexcom's CGM systems among insulin-dependent Type 2 patients, the relative lack of evidence of a benefit is severely limiting the company's total revenue.

In 2017, the American Diabetes Association estimated the number of Type 1 diabetes cases in the U.S. at 1.3 million. In 2012, it estimated the number of Type 2 diabetes patients at 27.8 million.

Go here to see the original:
Dexcom and University of Virginia to Advance Diabetes Research Together - Motley Fool

My name is Dr. Vishwanath Pattan and I am the Medical Director of Endocrinology at Wyoming Medical Center in Casper. Endocrinology is the study of hormones, and as an endocrinologist I treat patients for a wide variety of diseases related to hormonal deficiencies and imbalances. That includes many patients with diabetes.

At my clinic, Wyoming Endocrine and Diabetes, I treat patients from across Wyoming, and I have noticed an alarming trend for my diabetic patients in relation to the COVID-19 pandemic: an inability to monitor and control glucose or maintain weight in the summer months.

In a typical year, diabetic patients tend to lose weight and achieve better glucose control in the summer because they are able to live a much more active outdoor lifestyle. During the winter, I often see the opposite trend of added weight, less stable glucose levels, seasonal depression, and an increase in overall stress.

2020, however, has not been a typical year, and I have noticed a deviation from the typical summer pattern in my diabetic patients. Many of these patients have actually gained weight, exhibited less than stable glucose control, and had an increase in their overall stress levels.

I have a few theories on why this might be. When COVID-19 was first acknowledged as a public safety concern, people were quick to stock up on everything they could. As we know, the shelf life of heavily processed foods is what makes them some of the first to go amidst a global crisis.

These foods are built to stand the test of time, but for a diabetic patient, they can easily contribute to an unsafe fluctuation of glucose. There was also a lot of uncertainty, fear, and confusion that caused millions to be left without a job and the added stress of strict isolation measures. People were forced to live a much more sedentary lifestyle, whether they wanted to or not, and eat food that does not promote a healthy glucose level. I also saw a major decrease in correspondence with many of my patients with uncontrolled diabetes, further contributing to an atypical summer for the diabetic population.

So, why does this raise a red flag?

Although patients with diabetes are not at any further risk of contracting COVID-19, they are much more likely to suffer greater complications because of it. These complications could lead to the need for ventilator support, further intensive care, and even higher death rates by several folds. This leads me to my main concern with so many of my diabetic patients experiencing poor glucose control prior to a season in which it is already difficult to manage: A person with uncontrolled diabetes in the summer is more likely to have uncontrolled diabetes in the winter, especially during a global pandemic. With the dual-threat of COVID-19 and this upcoming flu season, it is paramount that people with diabetes put their health and safety at the forefront.

I strongly urge people with diabetes and their families to safely support one another through the winter months with the helpful information discussed below.

People with diabetes should:

Monitor glucose regularly, per your healthcare providers recommendation

Make sure to follow up with your healthcare providers, either in person or by utilizing virtual visits. (Healthcare facilities take utmost care and precautions, and put your health as a top priority, so in-person visits should be safe). In the coming months, it is essential to keep your providers up-to-date on your progress, and you should discuss individualized glucose goals with your doctor

Contact your healthcare provider immediately if your blood glucose is above target

Remain compliant with medication regimens and dietary treatment plans

Aim to eat a balanced diet, exercise regularly and get adequate sleep at least between 7 and 8 hours per night

Maintain a healthy immune system by prioritizing glucose control, managing stress levels and taking a Vitamin D supplement. In Wyoming, most people are naturally deficient during the winter months and are encouraged to seek their healthcare providers recommendation for proper supplementation.

Family members of diabetic patients should:

Encourage your loved one to keep appointments with healthcare providers

Assist them with technology for virtual visits

Avoid social gatherings, practice proper hand hygiene, and always wear a mask in public spaces to keep your loved one safe

Help with cooking balanced and healthy meals

Ensure that your loved one has at least 4 to 6 weeks worth of diabetic supplies on hand in case of supply issues later on. These include testing strips, insulin, and necessary insulin administration equipment

Remind patients to take their medication on time and encourage compliance with glucose monitoring

Help to maintain a stress-free environment at home

The rest is here:
Concerning trend found in patients with diabetes - Green River Star

Consuming more than 3 cups/day of white ricesignificantly increases the risk of diabetes compared with eating lower amounts, a new analysis of the multinational, multiethnic Prospective Urban Rural Epidemiology (PURE) study suggests.

In addition, the results show that those living in South Asian countries ate the most white rice and subsequently had the highest likelihood of developing type 2 diabetes.

Compared with participants who ate less than 1 cup/day (150 g/day) of cooked white rice, those who ate more than 3 cups/day (> 450 g/day) had a 20% higher risk of developing diabetes over a mean follow-up of 9.5 years (P = .003).

However, among South Asian participants, who consumed a median of 630 g/day of white rice, the risk of diabetes was 61% higher compared to those who consumed less than 150 g/day (P = .02), Balaji Bhavadharini, MD, McMaster University, Hamilton, Ontario, Canada, and colleagues report in their article, published online in Diabetes Care.

As the authors point it, excess white rice consumption, in particular, is known to lead to postprandial glucose spikes. These spikes, in turn, trigger compensatory hyperinsulinemia to help maintain euglycemia.

"Over time, -cells become exhausted, leading to -cell failure and diabetes," the researchers write.

"Among people of middle and lower socioeconomic status, rice consumption is very high because other food choices meat, fish, chicken, vegetables, and fruits are all quite expensive," second author Viswanathan Mohan, MD, PhD, DSc, chairand chief diabetologist at Dr. Mohan's Diabetes Specialties Centre, India, told Medscape Medical News in an email.

"Hence, people make up the calories [they need] by eating 'polished' rice. What we are suggesting is that protein intake should be increased, and this can come...in the form of beans and legumes, whichif consumed along with the rice, would help reduce the overall glycemic load of the diet," he added.

A total of 132,373 participants aged 35 to 70 from 21 different countries were included in the new analysis, which excluded anyone with diabetes at baseline.

Cooked white rice consumption was categorized as less than 1 cup (< 150 g/day); 1 to 2 cups (150 to < 300 g/day); 2 to 3 cups (300to < 450 g/day), or more than 3 cups/day (> 450 g/day). In the overall cohort, the median consumption of white rice was 128 g/day.

Participants from South East Asia (Indonesia, Malaysia, Thailand, Vietnam, and Cambodia, among other countries) ate a median of 239 g/day of white rice, while those from China ate a median of 200 g/day, investigators note.

Those living in South Asian countries (including India, Pakistan, Bangladesh, Nepal, Bhutan, Sri Lanka and the Maldives) ate the most white rice, at a median of 630 g/day.

During the study interval, 6129 individuals developed incident diabetes.

Among those living in South East Asia, the Middle East, South America, North America, Europe, and Africa, the risk of diabetes was 41% higher among those with the highest levels of white rice consumption compared to those with the lowest levels(P = .01), the investigators report.

And as already noted, the risk was even higher, at > 60%, in those living in South Asia.

In contrast, the effect of consuming the greatest quantity of white rice versus the lowest on diabetes risk was minimal among Chinese participants and did not reach statistical significance, the authors note.

"There could be several reasons for this," Mohan said. "Firstly, the actual intake of white rice in China was substantially lower than it was in other countries, especially among those living in South Asia. Secondly, the type of rice the Chinese consume may be slightly different than elsewhere in that it is 'sticky,'" he speculated.

Probably more importantly, however, "in China, they do consume a lot of animal protein as well as vegetable protein," he noted.

In contrast, protein intake tends to be low and carbohydrate intake mostly in the form of white rice is higher in South Asia than in any other region of the world.

In fact, in South Asia white rice makes up 70% to 75% of a typical person's daily calorie intake, Mohan observed.

As the authors point out, until a few decades ago, most of the rice consumed in India was pounded by hand, or "unpolished," and thus was a much coarser grain, similar to brown rice. But this fell out of favor because it's easier to store highly polished white rice than brown rice, which turns rancid more quickly.

In addition, there were only a handful of rice mills in India until the early 1970s, a situation which has now completely changed: there are now over a million rice mills in the country.

"This naturally led to increased consumption of high polished white rice," Mohan emphasized, "and in general, people like the color, taste, and smell of white rice better [than brown rice] plus brown rice takes longer to cook and is difficult to chew," he noted.

The solution to this public health conundrum is multifold. As Mohan sees it, the most obvious solution is to reintroduce brown rice as a widespread food commodity and make it less expensive than white rice.

Alternatively, food manufacturers could develop healthier varieties of white rice with resistant starch that would lower both the glycemic index and overall glycemic load, he observed.

People also need to be encouraged to increase their intake of beans, legumes, and other types of vegetable proteinsor pulses, which in India include chickpeas, green gram, black gram, and thoor dal. When these are consumed along with white rice, it improves the overall quality of the diet and would be expected to reduce the risk of diabetes.

Lastly, people need to be encouraged to be more physically active, which would also help reduce obesity rates and with it, diabetes risk, Mohan emphasized.

The study was funded by a number of pharmaceutical companies including AstraZeneca, Sanofi, Boehringer Ingelheim, Servier, and GlaxoSmithKline.

Bhavadharini and Mohan have reported no relevant financial relationships.

Diabetes Care. Published online September 1, 2020. Abstract

For more diabetes and endocrinology news, follow us on Twitter and Facebook.

View post:
More Proof That High White Rice Intake Ups Type 2 Diabetes Risk - Medscape

People with diabetes have a more difficult time regulating their blood sugar. Those with type 1 diabetes are not able to produce insulin, the hormone that helps the body convert blood sugar into energy. And those with type 2 diabetes cannot use insulin effectively.

As a result, blood sugar levels are often much higher for people with diabetes, especially in the morning. Here's why.

As your body prepares to wake for the day, it releases glucose stored in the liver to give you the energy you need to get going. However, people with diabetes are not able to utilize this blood sugar, so roughly half of diabetics experience high blood sugars in the morning. This is known as the dawn phenomenon.

If you have diabetes, your doctor will work with you to set a target range for your blood sugars. In general, blood sugar levels between 70 to 130 mg/dl are considered healthy for diabetes.

If your levels are consistently above your target in the morning, and you have not eaten yet, you might be experiencing dawn phenomenon. This is most common in people with type 2 diabetes.

Blood sugars typically peak about 2 to 3 hours before waking and can remain high as you wake up. For most people, that means the early morning hours, but if you have an abnormal sleep schedule you can experience this spike at any time.

"For individuals who work night shifts, the 'dawn' phenomenon may occur at dusk, since it's related to an individual's normal waking time, not the specific time of the day," says Joseph Barrera, MD, an endocrinologist with Mission Hospital in Orange County, California.

The Somogyi effect is a second explanation for high blood sugars in the morning, and this occurs most often in people with type 1 diabetes. It happens when people experience hypoglycemia or low blood sugar during the night. In an attempt to correct that, the body releases more stored glucose, which can then lead to high blood sugars in the morning.

The Somogyi effect is more rare than the dawn phenomenon, but that's mostly because fewer people have type 1 diabetes than type 2 diabetes. When a 2015 study published in Diabetology & Metabolic Syndrome followed 85 people with type 1 diabetes, it found that 82.4% of them had high blood sugars in the morning, and 60% of those were caused by the Somogyi effect, compared with just 12.9% caused by the dawn phenomenon.

To determine if your high blood sugars in the morning are caused by the Somogyi effect, Barrera says you'll need to see your blood sugar levels about 4 to 5 hours before you wake up, which can be done with a continuous glucose monitor.

You should talk to your doctor if you regularly experience high blood sugars in the morning, Barrera says. Your team will make recommendations on changing your treatment regimen that might help you avoid this morning hyperglycemia.

"High blood sugars in the morning can generally be addressed by careful attention to a diet and exercise regimen, and adjustments in diabetic medication by a qualified health professional," Barrera says.

To avoid dawn phenomenon, your doctor might tell you to take these steps:

People who continue to have trouble with the dawn phenomenon might be advised to take insulin before bed, Barrera says. However, this has to be done carefully, so that it doesn't cause the Somogyi effect.

People who experience the dawn phenomenon often find that it gets worse over time. In fact, it's considered an indicator that diabetes is progressing, so it's important to talk to your doctor about treating it.

On the flip side, making the necessary changes to regulate the dawn phenomenon can lower blood sugar over time. In fact, research has found that it can result in a 0.5% decrease in A1C levels a long-term measure of blood sugar which can reduce your risk for health complications from diabetes.

See original here:
Why your blood sugar is high in the morning and how to lower it - Insider - INSIDER

The global Millimeter Wave Diabetes Treatment Devices market is segregated on the basis of Type as Under 50 GHz and Above 50 GHz. Based on Application the global Millimeter Wave Diabetes Treatment Devices market is segmented in Type 1 Diabetes and Type 2 Diabetes.

The global Millimeter Wave Diabetes Treatment Devices market report scope includes detailed study covering underlying factors influencing the industry trends.

Browse Full Report: https://www.marketresearchengine.com/millimeter-wave-diabetes-treatment-devices-market

The global Millimeter Wave Diabetes Treatment Devices market report provides geographic analysis covering regions, such as North America, Europe, Asia-Pacific, and Rest of the World. The Millimeter Wave Diabetes Treatment Devices market for each region is further segmented for major countries including the U.S., Canada, Germany, the U.K., France, Italy, China, India, Japan, Brazil, South Africa, and others.

Competitive Rivalry

Zimmer MedizinSysteme, Smiths Group, Domer Laser, Hubei YJT Technology and others are among the major players in the global Millimeter Wave Diabetes Treatment Devices market. The companies are involved in several growth and expansion strategies to gain a competitive advantage. Industry participants also follow value chain integration with business operations in multiple stages of the value chain.

The Millimeter Wave Diabetes Treatment Devices Market has been segmented as below:

Millimeter Wave Diabetes Treatment Devices Market, By Type

Millimeter Wave Diabetes Treatment Devices Market, By Application

Millimeter Wave Diabetes Treatment Devices Market, By Region

Millimeter Wave Diabetes Treatment Devices Market, By Company

The report covers:

Report Scope:

The report covers analysis on regional and country level market dynamics. The scope also covers competitive overview providing company market shares along with company profiles for major revenue contributing companies.

The report scope includes detailed competitive outlook covering market shares and profiles key participants in the global Millimeter Wave Diabetes Treatment Devices market share. Major industry players with significant revenue share include Zimmer MedizinSysteme, Smiths Group, Domer Laser, Hubei YJT Technology, Application C10, Application B10, Application B8, Application B9, Application B10, Application C10, and others.

Reasons to Buy this Report:

Request Sample Report from here: https://www.marketresearchengine.com/millimeter-wave-diabetes-treatment-devices-market

Table of Contents:

Other Related Market Research Reports:

Medical Ultrasound Knife Market 2019 Demand, Size, Growth Research Report by 2024 MRE Analysis

About MarketResearchEngine.com

Market Research Engine is a global market research and consulting organization. We provide market intelligence in emerging, niche technologies and markets. Our market analysis powered by rigorous methodology and quality metrics provide information and forecasts across emerging markets, emerging technologies and emerging business models. Our deep focus on industry verticals and country reports help our clients to identify opportunities and develop business strategies.

Media Contact

Company Name: Market Research Engine

Contact Person: John Bay

Email: [emailprotected]

Phone: +1-855-984-1862

Country: United States

Website: https://www.marketresearchengine.com/

More:
Millimeter Wave Diabetes Treatment Devices Market Size, Share 2020 Growth Analysis, Share, Demand By Regions, Types And Analysis Of Key Players-...

ThursdaySep24,2020at11:08AM

DURHAM The University of New Hampshire announced it will receive $1.8 million from the National Institutes of Health to further molecular research to better understand drug interactions at the cellular level and help lead to the development of new targeted drugs to treat wide-spread metabolic, growth, neurological and visual disorders including diabetes and cancer.

"This is an exciting opportunity to support some of our preliminary research that showed promise in new protein drug targets involved in several diseases," said Harish Vashisth, associate professor of chemical engineering and recipient of the NIHs Outstanding Investigator award. "The NIH MIRA award (Maximizing Investigators' Research Award) is meant to provide flexibility to investigators and will allow us to explore new ideas and change direction based on our findings during the process."

Vashisth and his team will use computational techniques combined with experimental data to explore new and more suitable stages in the signaling cycle of a cell protein to target drug interventions. One of the studies will focus on better understanding the folding and binding mechanisms of novel peptides, a short string of amino acids that are building blocks of proteins and perform biological functions. Researchers will look at how they affect cell surface receptor proteins, part of the tyrosine kinase family, to signal responses within the cell. Small peptides can fold and bind to the receptor and mimic the normal physiological effects of natural peptides. The goal is to understand the folding and binding and ultimately find drugs to work around the fold.

"Imagine a cell as a flexible bag with the outer surface as the cell membrane containing proteins that act as gate keepers to communicate, or sense, specific conditions outside the cell that in turn trigger a cascade of signaling inside the cell," said Vashisth.

Their second research project will take an unconventional approach to target protein-protein interactions in proteins inside the cell, part of the G-protein coupled receptor family, that are important in touch, smell and sight and are implicated in many diseases. This work would create new small molecule drugs that would cross inside the membrane rather than bind to an outside receptor. These drugs would be synthetic and not naturally occurring.

Read this article:
UNH receives $1.8 million for biomolecular research in diabetes and cancer - Seacoastonline.com

The scientists concluded that HIIT can help in improving the blood sugar levels and can also help in losing weight effectively.

Representational image. Reuters

Diabetes is one of the major health burdens in the entire world. According to the International Diabetes Federation, more than 463 million adults in the age group of 20 to 79 years were living with diabetes in the year 2019.

Among these, a majority of people have been reported to have type 2 diabetes. Type 2 diabetes is the result of reduced insulin sensitivity in the body, which mostly occurs due to excess body weight and physical inactivity.

It is already known that physical activity helps in managing and preventing type 2 diabetes. However, it has been reported that most commonly practised aerobic exercises such as walking or jogging provide only 10 percent to 20 percent improvement in insulin sensitivity.

As per the new study, presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in September 2020, it was stated that insulin sensitivity, body composition and cardiorespiratory systems of people with obesity along with type 2 diabetes can be improved by combining high-intensity interval training (HIIT) with cycling and rowing.

Determining the effect of HIIT on obese and diabetic people

To determine the effects of HIIT, scientists from the Steno Diabetes Centre Odense, Odense, Denmark, enrolled 48 men in the study and divided them into three groups.

Out of the 48, 15 participants were obese with an average Body Mass Index (BMI) of 31 (kg/m2) and had been diagnosed with type 2 diabetes. The other two groups had non-diabetic participants, out of which 15 were obese with an average BMI of 31 and the rest 18 were lean with an average BMI of 24.

Body mass index, also known as BMI, is a way to measure whether or not a person is overweight or obese. An adult with a BMI that is between 18.5 and 24.9 is considered healthy, between 25 and 29.9 is considered overweight and 30 or over is considered obese.

All the participants underwent a highly supervised HIIT programme, which lasted for eight weeks. The participants had three training sessions per week, which were combined with cycling and rowing.

The effects of the training programme were evaluated with the help of Dual-energy X-ray absorptiometry (DXA) scans to determine the body changes, VO2 max tests to measure the amount of oxygen utilised during the session and euglycemic-hyperinsulinemic clamps along with indirect calorimetry to determine insulin sensitivity and metabolism.

The results of the study

In the beginning, people with diabetes showed around 35 to 37 percent reduction in insulin sensitivity as compared with the non-diabetic subjects.

However, after eight weeks of HIIT, the insulin sensitivity in lean men and those with only obesity was 32 to 37 percent on average whereas the average for the diabetic group was found to be 44 percent.

The scientists further found that after the training, the fasting blood sugar levels in patients with type 2 diabetes were also reduced. The HbA1c results, which measures the average level of blood sugar over the past 2 to 3 months, also showed a decline.

The body fat mass was reduced by 1.6 to 2.3kg in all three groups.

The VO2max results showed that oxygen utilisation increased by 10 percent in lean and obese people with no diabetes, while it increased to 15 percent in people with type 2 diabetes.

The scientists concluded that HIIT can help in improving the blood sugar levels and can also help in losing weight effectively. It is believed that the short bursts of intense anaerobic exercise with short recovery periods in between may prove to be better for people with obesity and diabetes in managing their condition.

For more information, read our article on High-Intensity Interval Training (HIIT).

Health articles in Firstpost are written by myUpchar.com, Indias first and biggest resource for verified medical information. At myUpchar, researchers and journalists work with doctors to bring you information on all things health.

Excerpt from:
HIIT along with rowing and cycling can help type 2 d..etes patients lose weight, improve insulin sensitivity - Firstpost

Why does diabetes make people particularly vulnerable to COVID-19? There is no persuasive evidence that this is because they are more likely to catch the virus in the first place and we, as yet, have no answers. Research is underway to understand the biological reasons why diabetes might allow the virus to get a firmer hold. A pro-inflammatory state, vascular damage, and upregulation of ACE2 receptors, all of which are associated with diabetes, have been suggested as potential contributors to severe COVID-19 in people with the condition7. The type of basic science needed to explore the virus mechanisms of attack and its interplay with diabetes takes time and is vital for understanding how we might better protect and care for people living with the condition.

Recently emerging is some limited and anecdotal evidence that COVID-19 might be triggering new cases of type 1 diabetes, accelerated progression of type 2 diabetes, or a new type of diabetes altogether. Again, we need to look to science for answers only long-term studies will reveal whats really going on and, crucially, help to inform care. To find answers, a global database of new cases of diabetes in patients with COVID-19, called the CoviDiab Registry Project, has been established8. The Post-HOSPitalisation COVID-19 (PHOSP COVID) study, a national consortium to understand and improve long-term health outcomes in people who have had the virus, will also shed light on the long-term implications of COVID-19 for people with diabetes.

Investment in science has never been more important. Last year, UK charities, including Diabetes UK, invested 1.9 billion into medical research more than half of all public spending nationally. But the sector is facing a dramatic and deeply concerning drop in income due to COVID-19 and research is at risk. The Association of Medical Research Charities (AMRC) has predicted a 310 million shortfall in research spend in 2020/21, with an estimated four-year recovery period.

AMRC and its members, including Diabetes UK, are urging the Government to commit to the Life Sciences Charity Partnership Fund (support at #Researchatrisk) co-investment scheme. This will allow medical research charities to emerge from this pandemic intact and in a strong position to continue to fund research that transforms healthcare and saves lives. Now more than ever, investment is needed in the sector to mitigate the impact of COVID-19 and future pandemics, on the health of the nation.

References

1 International Diabetes Federation, (2019). IDF Diabetes Atlas, 9th edn.Brussels, Belgium: IDF. Available at: https://www.diabetesatlas.org

2 Estimated from NCVIN (2016), Diabetes Prevalence Model for England + estimated growth between 20152020 from APHO (2010) Prevalence Models for Scotland and Wales.

3 Barron, E., Bakhai, C., Kar, P., Weaver, A., Bradley, D., Ismail, H., Knighton, P., Holman, N., Khunti, K., Sattar, N. and Wareham, N.J., (2020). Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole-population study. The Lancet Diabetes & Endocrinology.

4 Diabetes Prevalence Model. Quality and Outcomes Framework (QOF) 2017/18. Public Health England. Available at: https://fingertips.phe.org.uk/profile/diabetes-ft/data

5 Holman, N., Knighton, P., Kar, P., OKeefe, J., Curley, M., Weaver, A., Barron, E., Bakhai, C., Khunti, K., Wareham, N.J. and Sattar, N., (2020). Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort study. The Lancet Diabetes & Endocrinology.

6 Williamson, E.J., Walker, A.J., Bhaskaran, K., Bacon, S., Bates, C., Morton, C.E., Curtis, H.J., Mehrkar, A., Evans, D., Inglesby, P. and Cockburn, J., (2020). OpenSAFELY: factors associated with COVID-19 death in 17 million patients. Nature.

7 Apicella, M., Campopiano, M. C., Mantuano, M., Mazoni, L., Coppelli, A., & Del Prato, S. (2020). COVID-19 in people with diabetes: understanding the reasons for worse outcomes. The Lancet Diabetes & Endocrinology.

8 Rubino, F., Amiel, S. A., Zimmet, P., Alberti, G., Bornstein, S., Eckel, R. H., & Del Prato, S. (2020). New-Onset Diabetes in Covid-19. New England Journal of Medicine.

View original post here:
COVID-19 and diabetes: What do we (not) know? - Open Access Government